reported that the TIGIT blockade prevents NK cell exhaustion and enhanced the anti‐tumor response.[235] In 2020, Myers and Miller reviewed the research progress on NK cells and comprehensively summarized anti‐tumor immunotherapies targeting NK cells. The gene discussed is TIGIT; the disease is neoplasm.